Search results
Results From The WOW.Com Content Network
Following the news release, shares of the company closed at $43.12, denoting a slight decline in Friday’s trading session. ... NeoGenomics, Inc. (NEO), one of the foremost providers of cancer ...
NeoGenomics first received state and national-level laboratory certifications in 2002. Three years later in 2005, the company developed a technical-only service model using FISH. In 2013, the company launched its sequencing platform [3] and was listed on the Nasdaq Stock Market as NEO. In 2014, NeoGenomics launched molecular tests including BTK ...
NeoGenomics (NEO) delivered earnings and revenue surprises of -500.00% and 2.62%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In 2009 Doug VanOort was appointed CEORead More...
In the update, researchers noted that the children were all in various stages of neuroblastoma treatment when they underwent the trial. Five of the children had no evidence of disease during the ...
For premium support please call: 800-290-4726 more ways to reach us